KalVista Pharmaceuticals, Inc. was recognized by Fierce Pharma.
Public source
Publisher name
Public post
https://lnkd.in/gZXgehrC I am proud to see KalVista recognized by Fierce Pharma and to have been part of such an extraordinary chapter. Building something different requ…
Company
KalVista Pharmaceuticals, Inc.
Advancing novel medicines to empower everyday lives.
- Industry
- Biotechnology Research
- Location
- Framingham, US
- Company size
- 201–500 employees
About KalVista Pharmaceuticals, Inc.
For nearly a decade, KalVista Pharmaceuticals has been focused on addressing the critical unmet needs of those living with hereditary angioedema (HAE). With more than 250 employees worldwide, we leverage our team’s vast knowledge and expertise across all aspects of research, development, and commercialization to redefine the future of HAE treatment and advance global care for those who need it most.
See moreLatest activity
Latest activity from KalVista Pharmaceuticals, Inc.
5 signals
Presence & Recognition
KalVista Pharmaceuticals, Inc. is attending the 8th Bradykinin Symposium in Berlin, focusing on the kallikrein-kinin system and hereditary angioedema care.
Products & Services
KalVista Pharmaceuticals, Inc. successfully launched EKTERLY.
Presence & Recognition
KalVista Pharmaceuticals, Inc. supported the Hereditary Angioedema Association - HAEA Grassroots Advocacy Network that met this summer in Washington D.C.
Discover more
Similar signals
Similar public activity from other companies.
Presence & Recognition
Revolution Medicines
Revolution Medicines was named as a Fierce Pharma Breakthrough Honoree by Fierce Pharma.
Presence & Recognition
Veru Inc.
Veru Inc. announced that Veru Pharma has advanced oral Sabizabulin following an activity report.
Presence & Recognition
Verastem Oncology
Verastem Oncology was named a 2026 Fierce 50 honoree in the Breakthrough category by Fierce Pharma Fierce Biotech FierceHealthcare for its U.S. FDA-approved treatment specifically for adults with KRAS-mutated recurrent low-grade serous ovarian cancer.
Presence & Recognition
Intellia Therapeutics, Inc.
Intellia Therapeutics, Inc. was named a 2026 Fierce 50 honoree in the Breakthrough category.
Presence & Recognition
Kymera Therapeutics